Business Context and Reporting Period
This Form 6-K filing by Therapix Biosciences Ltd. (referred to as "Scisparc Ltd." in metadata) covers the month of July 2020, with the report dated July 1, 2020. The Company is a foreign private issuer based in Israel. The filing primarily addresses a private placement transaction, a regulatory delisting notice from Nasdaq, and a temporary injunction issued by an Israeli court.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins for the reporting period. The primary financial data relates to a capital raise:
- Private Placement: Agreements entered on June 29, 2020, for the issuance of 5.2 million American Depositary Shares (ADSs) at $0.50 per ADS.
- Warrants: Included warrants to purchase up to 2.6 million ADSs.
- Total Proceeds: The transaction is valued at approximately $2.6 million.
- Debt and Liquidity: The filing text does not provide specific values for existing debt or current liquidity positions.
Material Changes and Events
Three significant events constitute the material changes reported in this filing:
- Delisting Notice: On June 30, 2020, the Company received notice from the Nasdaq Hearings Panel to delist its ADSs from The Nasdaq Capital Market. Trading suspension was effective at the open of business on July 2, 2020.
- Court Injunction: On June 30, 2020, the Tel Aviv District Court granted a temporary injunction against the Company. This prohibits changes to share capital or resolutions outside the ordinary course of business until a hearing scheduled for July 8, 2020.
- Transaction Delay: Due to the court injunction, the closing of the $2.6 million private placement, originally scheduled for July 1, 2020, was delayed.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The Company intends to file a registration statement with the SEC to register the resale of the ADSs and warrants. The Company may request a review of the Nasdaq delisting decision within 15 days of the notice.
Risks and Contingencies:
- Legal Uncertainty: The temporary injunction creates immediate uncertainty regarding the ability to close the private placement and raise capital.
- Market Status: The Company faces delisting from Nasdaq, which may impact investor access and liquidity.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results regarding the private placement and use of proceeds may differ materially from expectations due to risks outlined in the Company's Form 20-F.
Investor Verification Checklist
- Verify the outcome of the Tel Aviv District Court hearing scheduled for July 8, 2020, to determine if the private placement can proceed.
- Confirm the status of the Company's appeal regarding the Nasdaq delisting decision.
- Review the attached press releases (Exhibits 99.1 and 99.2) for detailed terms of the purchase agreements and specific reasons for the delisting.
- Monitor subsequent filings for the registration statement required to allow resale of the newly issued securities.